Ticker: CLRB

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Quick take: management is cutting spending after finishing enrollment in its pivotal CLOVER WaM study, has FDA Breakthrough Therapy designation for iopofosine I‑131, but remains capital‑constrained with a formal going‑concern warning and material weaknes...